Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.45 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31509828 | 1.00 | ALDH1A1 (0.45) | ALDH1A1HPGDKDM4EHSD17B10HTT | |
| SCHEMBL15516982 | 0.84 | KDM4E (0.57) | ALDH1A1HPGDKDM4EHSD17B10HTT | |
| SCHEMBL27192197 | 0.82 | ALDH1A1 (0.51) | ALDH1A1HPGDKDM4EHSD17B10HTT | |
| SCHEMBL31509761 | 0.82 | ALDH1A1 (0.51) | ALDH1A1HPGDKDM4EHSD17B10HTT | |
| SCHEMBL31059905 | 0.82 | ICAM1 (0.38) | ALDH1A1HPGDKDM4EGAALMNA | |
| SCHEMBL5550510 | 0.79 | ALDH1A1 (0.46) | ALDH1A1HPGDKDM4EHSD17B10HTT | |
| SCHEMBL3816392 | 0.78 | LMNA (0.48) | ALDH1A1HPGDKDM4EHSD17B10GLA | |
| SCHEMBL31059924 | 0.75 | HSD17B10 (0.44) | ALDH1A1HPGDKDM4EHSD17B10HTT | |
| SCHEMBL15517761 | 0.73 | KDM4E (0.58) | ALDH1A1HPGDKDM4EHSD17B10HTT | |
| SCHEMBL7855369 | 0.73 | ALDH1A1 (0.43) | ALDH1A1HPGDKDM4EHSD17B10HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4565574-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-11 | — | — | EP | disclosed |
| CN-119731159-A | SARS-CoV2 main proteinase inhibitor | 吉利德科学公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| WO-2024031089-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| EP-1753428-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABBOTT LABORATORIES | 2006-04-06 | — | — | US | disclosed |
| WO-2005110410-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | ALDH1A1 3259/4885HPGD 2198/4885KDM4E 3744/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | ALDH1A1 3259/4885HPGD 2198/4885KDM4E 3744/4885 |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | ALDH1A1 3259/4885HPGD 2198/4885KDM4E 3744/4885 |
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABL1, MAP3K19, MAP3K20 | ALDH1A1 2415/4885HPGD 3775/4885KDM4E 965/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | ALDH1A1 3259/4885HPGD 2198/4885KDM4E 3744/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | ALDH1A1 3259/4885HPGD 2198/4885KDM4E 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.